Kornimate/medical-research-clean huggingface dataset:
treatment of residual refraction errors 6 months after trifocal iol implantation with relex-smile

Conditions: Pseudophakia; Myopia; Hyperopia

Summary: successful treatment of residual refraction 6 months after iol implantation with relex-smile.

residual refractive errors(myopia 50% and hyperopia 30%) are the main problems at patients after iol implantation. the residual refraction (myopic and hyperopic) after iol implantation is difficult to treat surgically. in addition, there are not many suitable options to offer such patients presenting with this condition. two current common surgeries to treat residual hyperopic refraction are refractive lens exchange (rle) and excimer laser ablation (lasik or prk). laser procedures: photorefractive keratectomy (prk); laser assisted in situ keratomileusis (lasik); risks of lasik include abnormalities of the corneal flap, epithelial ingrowth, corneal ectasia, refractive surprises, irregular astigmatism, decentration, visual aberrations, a loss of bcva, infectious keratitis, symptoms, and diffuse lamellar keratitis. refractive lens exchange (rle); the risks of rle are similar to those of cataract surgery and include endophthalmitis, a loss of accommodation, vitreous loss with posterior capsular rupture, and retinal detachment. the aim of our study is to investigate the effect of relex-smile to treat the residual refraction errors (myopia and hypermetropia) 6 months after iol implantation. before smile, yag-laser capsulotomy should be performed on all patients, regardless of posterior capsule ossification, in pseudophakic patients with residual refraction. when the yag laser is applied after the smile ,there will be a diopter change. in pseudophakic patients with hyperopic astigmatism and residual refraction ,corneal topography-guided intrastromal fresh lenticular implantation should be performed and the lenticule was placed according to the low k value. at myopic residual refraction(-0.75d till -5.50d) after iol implantation the method used at the eye hospital pristina by relex-smile is safe and effective method, since there is no flap and this prevents invasive damage to the anterior surface of the cornea contrary to the lasik where flap is present posing risk for epithelial ingrowth. at hyperopic residual refraction this study is to investigate the effect of fresh myopic corneal lenticule implantation as allogenic implant(-1.50d) that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropia refraction (+1.0d) using visumax femtosecond laser - smile module surgery

Eligibility criteria:
inclusion criteria: * residual hypermetropic, myopic refraction on pseudophakic patients * low visual acuity exclusion criteria: * active anterior segment pathologic features, * previous corneal or anterior segment surgery, * glaucoma, * retinal detachment
the proteins of the contact activation system

Conditions: Factor XI Deficiency; Factor XII Deficiency

Summary: cardiovascular diseases are important causes of morbidity and mortality in the industrialized world. abnormalities in the coagulation system, causing a hypercoagulable state, are a known risk factor for arterial and venous thrombosis. the contact activation system is part of the coagulation system and consists of four proteins: coagulation factor xii (fxii), fxi, prekallikrein and high molecular weight kininogen (hmwk). clinical studies indicate an important role for the contact activation system on the risk of arterial thrombosis. furthermore, there is substantial evidence from mouse studies that fxii and fxi participate in the formation and stability of thrombi. in vitro studies show that collagen, present in the vascular wall, is able to activate fxii and hereby stimulate thrombin formation and potentiate the formation of platelet-fibrin thrombi and fxiia is able to change the structure of fibrin clots by binding to fibrin(ogen) and by generation of additional thrombin. however, the contact system also participates in the process of fibrinolysis, which degrades thrombi. the investigators would like to investigate the contribution of the contact activation system to the formation of thrombi. the formation of a thrombus within the vascular bed is the main cause for occlusion of an artery or vein, which can lead to an infarct such as a heart attack. due to the other functions of the contact system it is important to fully understand how the contact system contributes to thrombus formation, before it can be used as a target in the treatment of arterial thrombosis. the aim of this study is to determine the contribution of the proteins of the contact system, mainly fxii and fxi, in the platelet mediated formation and degradation of thrombi. this will be studied in flow models (perfusion-flow model and chandler loop), in a static model (rotem®) and using thrombin generation assay.


Eligibility criteria:
inclusion criteria: * deficiency in coagulation factor xii and factor xi (factor level\<5%) * subjects of both gender * age ≥18 and ≤ 65 * written informed consent from the subject * subject with a social security plan or beneficiary of such a plan. exclusion criteria: * age below 18 * age above 65 * other known abnormalities of the coagulation system * thrombocytopenia * known platelet disorders * personal history of severe liver diseases * symptoms of active disease (e.g. cancer) * the use of antiplatelet drugs * the use of drugs that interfere with coagulation * ongoing diagnosed pregnancy upper 3 months * adult patients protected by law * concomitant participation to a biomedical research

Keywords: contact system factor xi deficiency factor xii deficiency global haemostasis assays
ipm procedures with or without fluoroscopy: outcome comparison

Conditions: Low Back Pain; Neck Pain

Summary: to determine clinically significant improvement in the patients undergoing procedures under fluoroscopy. to evaluate and compare the adverse event profile in both groups

for the target delivery of injectate, it is believed that fluoroscopy is mandatory. however, there is a view among some professionals that a procedure may be performed without fluoroscopy as effectively as under fluoroscopy. the outcomes among the two groups of patients have not been studied

Eligibility criteria:
inclusion criteria: patients who have undergone the following procedures: cervical facet joint nerve blocks, thoracic facet joint nerve blocks, lumbar facet joint nerve blocks, lumbar interlaminar epidural steroid injections, cervical interlaminar epidural steroid injections during 1998 to 2001 and 2004 to 2005 - exclusion criteria: non-availability of appropriate data

Keywords: fluoroscopy interventional pain management procedures
yogurt for prevention of chronic inflammation

Conditions: Obesity; Inflammation

Summary: the objective of this study is to conduct a randomized cross-over dietary intervention in adult women who are overweight or obese to compare how yogurt and a control food affect biomarkers of inflammation and intestinal health.


Eligibility criteria:
inclusion criteria: * healthy premenopausal women age 21-55 * bmi ≥ 25 kg/m2 * not taking medication to control hypertension (e.g. anti-hypertensives or diuretics) * resting blood pressure \<140/90 mmhg * stable body weight for past two months * willing to maintain a normal exercise level (in general) * willing to avoid exercise and smoking (or other forms of nicotine intake) for 24 h prior to blood collection * willing to avoid caffeine for 12 h before study visits * willing to fast 12 h prior to study visits * willing to avoid dietary supplements, yogurt and probiotic-containing foods (as necessary) and consume 12 oz. of yogurt and the control food per day (as necessary) for the duration of the study exclusion criteria: * self-reported previous diagnoses of an inflammatory disease (e.g. inflammatory bowel disease, asthma, arthritis), cvd, diabetes, current cancer treatment (i.e., chemotherapy, radiation therapy) * have used oral antibiotics in the prior 21 days before sample collection * actively trying to lose weight * regularly taking anti-inflammatory drugs * vegetarian or allergic to soy or dairy * are pregnant, lactating, or trying to become pregnant

Keywords: yogurt obesity intestine
ultrasound-guided versus brainlab navigation sphenopalatine ganglion block in functional endoscopic sinus surgery

Conditions: Ultrasound; Brainlab Navigation; Sphenopalatine Ganglion Block; Functional Endoscopic Sinus Surgery

Summary: this study compares ultrasound-guided and brainlab navigation sphenopalatine ganglion block (spgb) in functional endoscopic sinus surgery (fess).

functional endoscopic sinus surgery (fess) is the treatment modality of choice for the inflammatory disease of paranasal sinuses. sphenopalatine ganglion block (spgb) is a regional analgesic technique that can be used as an alternative approach to reduce blood loss and improve the operative field during fess without the need for hypotensive agents. ultrasound (us)-guided nerve block is a well-established technique in regional anesthesia and offers the advantage of real-time visualization of neural and vascular structures.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years. * both sexes. * american society of anesthesiologists (asa) physical status i-ii. * patients undergoing functional endoscopic sinus surgery under general anesthesia. exclusion criteria: * patients having a history of severe renal, hepatic, respiratory, cardiac disease, or a neurological condition. * drug or alcohol abuse. * chronic pain requires major analgesics, sedatives, or corticosteroids. * pregnant and lactating women. * hypersensitivity to local anesthetic agents.
acute effects of beetroot juice on locomotor economy and capacity in chronic stroke

Conditions: Stroke; CVA

Summary: the purpose of this study is to investigate if a beetroot juice supplement can improve oxygen capacity during walking tasks at a submaximal and maximal effort in people greater than 6 months following stroke.

during this study, participants will perform baseline measurements such as walking and balance tests. during baseline testing, participants will be asked to perform a maximal exertion test while walking on a treadmill to determine the speed for a submaximal walking test. one week after baseline testing, the participant will have an intervention session where they drink either a beetroot juice supplement or a placebo. the placebo will taste similar to the beetroot juice and participants may not be able to tell the difference between the two different supplements. after a week, the participant will return to the lab and drink the other supplement. for example, if the participant drank the beetroot juice in the first session, then they will drink the placebo in the second session. during each intervention session, the participant will be asked to perform two treadmill tests, one with submaximal effort and one with maximal effort. after the walking tests, they will drink either the beetroot juice or placebo and have their blood drawn. they will wait at the hospital for 2-3 hours and have their blood drawn again. the participants will then complete the two treadmill tests again. the two intervention sessions will last about 4-6 hours for each session. participation in the study will last 4-6 weeks including screening and baseline testing.

Eligibility criteria:
inclusion criteria: * adults aged 18-89 years * diagnosis of chronic hemiparesis following unilateral stroke (greater than six months) * ability to ambulate at least 0.3 m/s, with or without using an assistive device or bracing below the knee * ability to read and understand english * follow three-step commands exclusion criteria: * presence of cerebellar deficits * any other neurological or orthopedic deficits that would limit walking ability * smoking * cannot receive physical therapy for gait-related impairments * uncontrolled metabolic, respiratory, and cardiovascular disease

Keywords: dietary nitrate beetroot juice high-intensity gait training
chemotherapy plus egfr monoclonal antibody in patients with liver metastases from colorectal cancer with ctdna superselective negative genes

Conditions: Liver Metastases of Colorectal Cancer

Summary: the purpose of this phase ii single-arm study is to prospectively explore the efficacy of chemotherapy plus egfr inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctdna superselective negative genes.


Eligibility criteria:
inclusion criteria: * 18-75 years (including 18 and 75 years); * ecog ps 0 or 1; * colorectal cancer diagnosed histologically and/or cytologically with metastatic or recurrent lesions that are not curable with surgery; * patients with liver metastases of ras wild-type colorectal cancer who have not received prior treatment; * at least one measurable lesion as defined in recist version 1.1; * fertile patients must be willing to take highly effective pregnancy avoidance measures during the study period and ≥120 days after the last dosing; female patients with negative urine or serum pregnancy test results within ≤7 days before the first administration of the study drug; * have fully understood the study and voluntarily signed the informed consent. * adequate organ and bone marrow function, meeting the following definitions: 1. blood routine (no transfusion, no use of granulocyte colony stimulating factor \[g-csf\], no use of other drugs for correction within 14 days before treatment); absolute neutrophil count (anc) ≥1.5×109/l; hemoglobin (hb) ≥9.0 g/dl; platelet count (plt) ≥80×109/l; 2. blood biochemistry, serum creatinine (cr) ≤ 1.5× upper limit of normal (uln) or creatinine clearance ≥60 ml/min; serum albumin ≥2.8g/dl. patients with poor nutritional status before neoadjuvant therapy could also be enrolled if they met the criteria through parenteral nutrition. total bilirubin (tbil) ≤ 1.5×uln; aspartate aminotransferase (ast) or alanine aminotransferase (alt) level ≤2.5×uln; exclusion criteria: * pregnant or lactating women; * patients with a known history of allergy to any investigative drug, similar drug, or excipient; * patients with risk of massive gastrointestinal bleeding or gastrointestinal obstruction; * patients with a history of thromboembolism, except thrombosis caused by picc; * there are patients with active infection; * patients with difficult to control hypertension (systolic blood pressure ≥160 mmhg and diastolic blood pressure ≥90mmhg); * patients with brain metastases with clinical symptoms or imaging evidence; * treatment contraindications exist in combination with other chronic diseases; * patients with previous immunotherapy-related myocarditis, pneumonia, colitis, hepatitis, nephritis and other conditions, and the current ae is still ≥ grade 2; * according to nci ctcae version 5.0 evaluation criteria, existing patients with various toxic and side effects caused by previous treatment ≥ grade 2; * other conditions that the investigator determined were not suitable for inclusion in the study. * received any anti-tumor therapy and participated in other clinical studies within 4 weeks before enrollment.
medical nutrition therapy program for pregnant women with diabetes

Conditions: Gestational Diabetes; Type 2 Diabetes

Summary: no dietary strategies have been designed and proved for mexican pregnant women with diabetes. this is a randomized clinical trial of pregnant women with pregestational type 2 diabetes and gestational diabetes that were followed every two weeks until labor to assess the impact of the mnt program on metabolic control, maternal and fetal nutritional status and cost effectiveness. participants were randomly assigned to one of three medical nutrition therapy (mnt) groups: the mnt 1 group (n=38) received usual medical treatment, counseling from a nutritionist and diabetes educator, using carbohydrate counting (40-45% of carbohydrates)with an intensive educational component; mnt2 group (n=50) had the same treatment, but included only low-moderate glycemic index foods; and no-mnt group (n=45) received the current hospital treatment. all women will receive a glucose meter so they do self glucose monitoring (pre and postprandial) 2 times a weeks 6 times a day. weight gain, dietary consumption and glucose concentrations will be evaluated every two weeks. fetal outcomes (weight, length and presence of complications)will be measured at labor.


Eligibility criteria:
inclusion criteria: * pregnant women with gestational diabetes (freinkle´s classification: type a2 and b1) or pregestational type 2 diabetes. * less than 30 weeks of gestation * women who plan to attend their pregnancy at the institution (inperier) exclusion criteria: * women with type 1 pregestational diabetes or gestational diabetes type a1. * women with multiple pregnancies * women with renal or hepatic disease * women who could not follow the dietary recommendations within the study

Keywords: gestational diabetes medical nutrition therapy program glucose monitoring metabolic control nutritional status cost effectiveness
efficacy of flywheel inertial resistance training in the architecture and function of the hamstring

Conditions: Hamstring Injury

Summary: investigate the efficacy of the inercial flywheel training protocol in modifying the architecture and function of the hamstrings in patients with a history of structural muscle injury vs conventional training. the researchers hypothesize that inercial flywheel training protocol will be a useful strategy in the modification of the architecture and function of the hamstring in patients with a history of indirect structural muscle injury and decrease the recurrence.

randomized controlled intervention study

Eligibility criteria:
inclusion criteria: * adults with history of structural muscle injuries type 3 of the munich consensus classification for muscular injuries, confirmed by imaging diagnosis no more than 2 years ago. * the patient must have performed conventional medical and physiotherapy treatment * have returned to their usual sporting activity * with good mental health. exclusion criteria: * suffer from a systemic pathology that could alter the healing biology of the muscle. * present other lesions in the muscular group of extrinsic characteristic or not encompassed within type 3 structural lesions such as, for example, proximal or distal insertion tendinopathy, use of semitendinous as anterior cruciate ligament graft. * prior knee or hip surgery. * having been infiltrated with platelet rich plasma in the posterior thigth region in the previus 3 months before startin the study

Keywords: hamstring injury flywheel inertial resistance hamstring architecture ultrasound eccentric
regional anesthesia in hip arthroscopy

Conditions: Femoroacetabular Impingement

Summary: the purpose of this research is to determine differences in outcomes in patients who receive regional anesthesia (a fascia iliaca block) versus placebo prior to undergoing hip arthroscopy with labral repair and/or debridement and osteoplasty for hip impingement.

methods: after informed consent is obtained at a routine/pre-surgical clinic visit, all patients who meet eligibility criteria will undergo randomization into one of two groups. these groups are 1) to receive regional anesthesia (a single shot fascia iliaca block using bupivacaine) prior to hip arthroscopy, or 2) undergo a subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water) instead of bupivacaine. intra-operatively, both groups will receive general anesthesia and local anesthesia (lidocaine and bupivacaine in the peripheral compartment).

Eligibility criteria:
inclusion criteria: * patient undergoing primary hip arthroscopy with labral repair and osteoplasty for hip impingement * age 18-45 years old * not pregnant * no history of neuropathic pain * no radiographic signs of osteoarthritis of the operative hip (tönnisgrade 1) * willing and able to comply with post-operative hip arthroscopy protocol * no documented allergy to anesthetic agents * able to attend follow up appointments exclusion criteria: * allergy to regional anesthetic * age \ 45 years * pregnant females * history of neuropathic pain * radiographic signs of osteoarthritis (tönnis grade 2) * unable to speak/understand english * currently imprisoned * unwilling/unable to provide consent
effects of cold and kinesio taping in individuals with rotator cuff tendonitis

Conditions: Rotator Cuff Tendinitis

Summary: rotator cuff tendonitis (rct) is one of the most common shoulder pathologies, causing pain, limitation of shoulder joint movements, and impaired function. patient education, medical treatment, corticosteroid injections, physiotherapy rehabilitation approaches are the most common treatment options applied to alleviate the symptoms of rct. despite these various treatment methods, there are currently no specific guidelines regarding the most appropriate and effective intervention for rct treatment. this is mainly because adequate, high-quality studies are lacking in rct management. to the best of our knowledge, no studies have evaluated the effects of kinesio taping (kt), which has become a popular approach in recent years, and cold therapy (ct), which has often been used as a therapeutic agent since immemorial, on individuals with rct. in this regard, this study aimed to investigate and compare the short-term effects of kt and ct on pain and upper extremity functionality in individuals with rct.


Eligibility criteria:
inclusion criteria: * rct diagnosis * excluding other shoulder pathologies by magnetic resonance imaging (mri) and specific tests exclusion criteria: * glenohumeral joint dislocation/subluxation; * acromioclavicular sprain; * rotator cuff tear; * glenohumeral joint instability; * calcific tendinitis of the shoulder; * acromioclavicular joint pathologies, * hyperlaxity; * any fracture in the shoulder; * diabetes, thyroid and any vascular or rheumatologic disease; * glenohumeral joint deformities; * superior labrum anteroposterior (slap) lesion; * shoulder pain lasting more than six months; * history of shoulder surgery; * intra-articular steroid injection
natural history study for pediatric patients with early onset of either gm1 gangliosidosis, gm2 gangliosidoses, or gaucher disease type 2

Conditions: GM1 Gangliosidosis; GM2 Gangliosidosis; Gaucher Disease, Type 2; Tay-Sachs Disease; AB Variant Gangliosidosis GM2; Sandhoff Disease

Summary: this study is being conducted to better understand the natural course of gm1 gangliosidosis, gm2 gangliosidoses and gaucher disease type 2 (gd2). information is planned to be gathered on at least 180 patients with gm1 gangliosidosis, gm2 gangliosidoses, and gaucher disease type 2. retrospective data collection is planned for at least 150 deceased patients (group a). group b is for patients alive at the time of enrollment. in group b it is planned to prospectively collect more comprehensive data from at least 30 patients. the purpose of this study is to collect relevant information for a adequate design of a potential subsequent research program in these diseases. in this study no therapy is being offered.


Eligibility criteria:
inclusion criteria: * patient with either gm1 gangliosidosis, gm2 gangliosidoses (tay-sachs, sandhoff, or ab variant), or gaucher disease type 2. * diagnosis confirmed by either biochemical (enzyme activity) or genetic testing, or both. * date of birth on or after 1 january 2000. * onset of first neurological symptom within 24 months of age. * informed consent of parent or legal guardian as required by local law.